Due to health issues, this site is no longer maintained and will be shut down shortly. |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
$8.15 -0.05 (-0.61%)
As of 03/27/2023 14:06:47 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.